HRAS and urothelial carcinoma: The objective of this study is to examine the efficiency of artemisinin as a cancer treatment alone and as a pre-treatment to cisplatin chemotherapy on high grade urothelial carcinoma in male albino mice by assessing biochemical parameters (kidney functions), hematological parameters (CBC) and histopathological examination (kidney and urinary bladder tissues), in addition to the expression of oncogenes (FGFR3 and HRAS) and tumor suppressor genes (P53 and KDM6A).